Sept ’14 BOSTON — A new report describes cases of progressive multifocal leukoencephalopathy (PML) that have been seen to date among patients with multiple sclerosis (MS) treated with fingolimod (Gilenya, Novartis Pharma AG), all but 1 of whom had previously been treated with natalizumab (Tysabri, Biogen Idec), known to carry a risk for PML.
The lingering question is whether there is any risk for PML with the new oral agent, but the authors suggest that the 1 patient not previously treated with natalizumab may have had neuromyelitis optica (NMO) rather than MS, and had several atypical features.
Tysabri does not clear the system for up to 6 months, authors report.
Read the entire article at: http://www.medscape.com/viewarticle/832307
You must be logged in to reply to this topic.